B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis

What Was Tested

The paper reports a study of Glatiramer Acetate in the context of multiple sclerosis, published as a clinical trial.

The researchers investigated the predictive value of the enzyme-linked immunospot technique (ELISPOT) in identifying patients with relapsing-remitting multiple sclerosis (RRMS) who will respond to treatment with glatiramer acetate (GA) or interferon-β (IFN-β), based on the brain-reactive B-cell activity of peripheral blood cells.

Why It Was Studied

This study provides Class II evidence that in patients with RRMS, the brain reactivity of their peripheral-blood B cells predicts clinical response to GA and IFN-β.

Who Took Part

According to the abstract, 73 patients were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

In this retrospective, cross-sectional, real-world multicenter study, the researchers identified patients with RRMS in the NeuroTransData MS registry and stratified them based on their documented treatment response (relapse-free in the first 12 months of treatment) to GA or IFN-β.

The GA group comprised 73 patients who responded to GA and 35 nonresponders.

How the Study Was Run

In design terms this was a multicenter study.

More than one site took part, so the patients came from several places.

The IFN-β group comprised 62 responders to IFN-β and 37 nonresponders.

Patients with previous or current therapy affecting B-cell activity were excluded.

The researchers polyclonally stimulated mononuclear cells from peripheral blood samples (collected after participant selection) and investigated brain-reactive B-cell activity after incubation on brain tissue lysate-coated ELISPOT plates.

Validity metrics of the ELISPOT testing results were calculated (Python 3.6.8) in relation to the clinical responsiveness in the 2 treatment groups.

What Was Measured

The subject headings attached to it are B-Lymphocytes, Brain, Cross-Sectional Studies, Glatiramer Acetate, Interferon-beta and Multiple Sclerosis, Relapsing-Remitting.

What This Means in Plain Language

The paper is a multicenter study of Glatiramer Acetate in 73 patients in people with multiple sclerosis.

Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2021 (Neurology(R) neuroimmunology & neuroinflammation), a journal based in United States.

More context: the Glatiramer Acetate compound page, Multiple sclerosis research.